Covid19 Clinical Trial
Official title:
Perceptions of Netizens Regarding COVID-19 Information & Information Sources: A Cross Sectional Study
NCT number | NCT04497441 |
Other study ID # | QassimU3 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 10, 2020 |
Est. completion date | August 15, 2020 |
COVID-19 Infection was characterized as a Pandemic by WHO on the 11th of March 2020.1 After
this there were all possible worldwide efforts to increase awareness in the general
population about the COVID-19 Infection signs, symptoms, mode of transmission and prevention.
The information was spread across all possible mass media communication channels. There were
constant updates regarding the data of newly infected cases, deaths, and recoveries. This
cross sectional study is conducted with the following objectives:
1. To understand the netizens perception regarding the sources of information available on
COVID-19.
2. To understand the netizens populations perception regarding the available information on
COVID-19.
Status | Recruiting |
Enrollment | 385 |
Est. completion date | August 15, 2020 |
Est. primary completion date | August 10, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years and older |
Eligibility |
Inclusion Criteria: - Male and Female Human volunteer internet users who belong &/or reside in Al Qassim province region of Saudi Arabia. - Volunteers should be major by age (18 years and above). Exclusion Criteria: - Minor age group (<18 years) subjects are excluded from the study. - Internet users who have preexisting phobia and/or anxiety mental conditions are excluded from the study. - Internet users who are currently under treatment for their preexisting phobia and/or anxiety mental conditions are excluded from the study. |
Country | Name | City | State |
---|---|---|---|
Saudi Arabia | Dr Bugude Shiva Shankar | Ar Rass | Al Qassim |
Lead Sponsor | Collaborator |
---|---|
Qassim University |
Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Netizens' perception of the Sources of COVID-19 information | Assessing the perception regarding the Sources of COVID-19 information among netizens in Al Qassim province using a 10 open ended Questionnaire. Descriptive statistics will be used to present the data. | 11th of August 2020 | |
Primary | Netizens' perception on COVID-19 information | Assessing the perception regarding COVID-19 information among netizens in Al Qassim province using a 6 open ended Questionnaire. Descriptive statistics will be used to present the data. | 11th of August 2020 | |
Secondary | Correlation of Age and the Frequency of checking COVID-19 information updates | The survey data will be statistically analyzed to check for the Correlation of Age and the Frequency of checking COVID-19 information updates. The data obtained from the survey will be subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed. | 11th of August 2020 | |
Secondary | Correlation of Gender and the Frequency of checking COVID-19 information updates | The survey data will be statistically analyzed to check for the Correlation of Gender and the Frequency of checking COVID-19 information updates. The data obtained from the survey will be subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed. | 11th of August 2020 | |
Secondary | Correlation of Age and the perception of newly infected COVID-19 cases information update | The survey data will be statistically analyzed to check for the Correlation of Age and the perception of newly infected COVID-19 cases information update. The data obtained from the survey will be subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed. | 11th of August 2020 | |
Secondary | Correlation of Age and the perception of COVID-19 deaths information update | The survey data will be statistically analyzed to check for the Correlation of Age and the perception of COVID-19 deaths information update. The data obtained from the survey will be subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed. | 11th of August 2020 | |
Secondary | Correlation of Age and the perception of COVID-19 Vaccine information update | The survey data will be statistically analyzed to check for the Correlation of Age and the perception of COVID-19 Vaccine information update. The data obtained from the survey will be subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed. | 11th of August 2020 | |
Secondary | Correlation of Age and the perception of COVID-19 treatment medicines/drugs information update | The survey data will be statistically analyzed to check for the Correlation of Age and the perception of COVID-19 treatment medicines/drugs information update. The data obtained from the survey will be subjected to appropriate analytical statistical tests to understand the correlation. A p-value of <0.05 is considered statistically significant correlation of the variables analysed. | 11th of August 2020 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |